Optimization of antigen dose for a receptorbinding domain-based subunit vaccine against MERS coronavirus

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 5, 2015, Pages 1244-1250

  Tang, Jian ^a,b,c   Zhang, Naru ^c   Tao, Xinrong ^d   Zhao, Guangyu ^b   Guo, Yan ^b   Tseng, Chien Te K ^d   Jiang, Shibo ^c,e   Du, Lanying ^c   Zhou, Yusen ^a,b  

^a Central South University   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c NEW YORK BLOOD CENTER   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

^e FUDAN UNIVERSITY   (China)

Author keywords

Antigen doses; MERS; MERS CoV; Receptor binding domain; Subunit vaccines

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; SUBUNIT VACCINE; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOLOGICAL ADJUVANT; MF59 OIL EMULSION; POLYSORBATE; SQUALENE; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CORONAVIRUS INFECTION; CYTOKINE RELEASE; CYTOPATHOGENIC EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMORAL IMMUNITY; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; RECEPTOR BINDING; VACCINATION; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CORONAVIRUS INFECTIONS; GENETICS; HUMAN; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CORONAVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN FC FRAGMENTS; MICE, INBRED BALB C; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; POLYSORBATES; RECOMBINANT FUSION PROTEINS; SQUALENE; VACCINES, SUBUNIT; VIRAL VACCINES;

EID: 84939161916     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1021527     Document Type: Article

References (43)

1. Drosten C, Seilmaier M, Corman VM, Hartmann W, Scheible G, Sack S, Guggemos W, Kallies R, Muth D, Junglen S, et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis 2013; 13: 745-51; PMID:23782859; http://dx.doi.org/10.1016/S1473-3099(13)70154-3
2. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, Flemban H, Al-Nassir WN, Balkhy HH, Al-Hakeem RF, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13:752-61; PMID:23891402; http://dx.doi.org/10.1016/S1473-3099(13)70204-4
3. Zaki AM, van BS, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367:1814-20; PMID:23075143; http://dx.doi. org/10.1056/NEJMoa1211721
4. Yang Y, Du L, Liu C, Wang L, Ma C, Tang J, Baric RS, Jiang S, Li F. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc Natl Acad Sci U S A 2014; 111:12516-21; PMID:25114257; http:// dx.doi.org/10.1073/pnas.1405889111
5. Ithete NL, Stoffberg S, Corman VM, Cottontail VM, Richards LR, Schoeman MC, Drosten C, Drexler JF, Preiser W. Close relative of human Middle East respiratory syndrome coronavirus in bat, South Africa. Emerg Infect Dis 2013; 19:1697-9; PMID:24050621; http:// dx.doi.org/10.3201/eid1910.130946
6. Lelli D, Papetti A, Sabelli C, Rosti E, Moreno A, Boniotti MB. Detection of coronaviruses in bats of various species in Italy. Viruses 2013; 5:2679-89; PMID:24184965; http://dx.doi.org/10.3390/ v5112679
7. Azhar EI, Hashem AM, El-Kafrawy SA, Sohrab SS, Aburizaiza AS, Farraj SA, Hassan AM, Al-Saeed MS, Jamjoom GA, Madani TA. Detection of the middle East respiratory syndrome coronavirus genome in an air sample originating from a camel barn owned by an infected patient. MBio 2014; 5:e01450-14; PMID:25053787; http://dx.doi.org/10.1128/ mBio.01450-14
8. Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem AM, Madani TA. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med 2014; 370:2499-505; PMID:24896817; http://dx.doi.org/10.1056/NEJMoa1401505
9. Reusken CB, Haagmans BL, Muller MA, Gutierrez C, Godeke GJ, Meyer B, Muth D, Raj VS, Smits-De VL, Corman VM, et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis 2013; 13:859-66; PMID:23933067; http:// dx.doi.org/10.1016/S1473-3099(13)70164-6
10. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med 2013; 368:2487-94; PMID:23718156; http://dx.doi. org/10.1056/NEJMoa1303729
11. Omrani AS, Matin MA, Haddad Q, Al-Nakhli D, Memish ZA, Albarrak AM. A family cluster of Middle East respiratory syndrome coronavirus infections related to a likely unrecognized asymptomatic or mild case. Int J Infect Dis 2013; 17:e668-72; PMID:23916548; http://dx.doi.org/10.1016/j. ijid.2013.07.001
12. Harriman K, Brosseau L, Trivedi K. Hospital-associated Middle East respiratory syndrome coronavirus infections. N Engl J Med 2013; 369:1761; PMID:24171525; http://dx.doi.org/10.1056/ NEJMc1311004
13. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, Alabdullatif ZN, Assad M, Almulhim A, Makhdoom H, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013; 369:407-16; PMID:23782161; http://dx. doi.org/10.1056/NEJMoa1306742
14. Lu L, Liu Q, Zhu Y, Chan KH, Qin L, Li Y, Wang Q, Chan JF, Du L, Yu F, et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun 2014; 5:3067; PMID:24473083
15. Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, Muth D, Demmers JA, Zaki A, Fouchier RA, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495:251-4; PMID:23486063; http://dx.doi.org/ 10.1038/nature12005
16. Gao J, Lu G, Qi J, Li Y, Wu Y, Deng Y, Geng H, Li H, Wang Q, Xiao H, et al. Structure of the fusion core and inhibition of fusion by a heptad-repeat peptide derived from the S protein of MERS-CoV. J Virol 2013; 87:13134-40; PMID:24067982; http://dx.doi.org/ 10.1128/JVI.02433-13
17. Lu G, Hu Y, Wang Q, Qi J, Gao F, Li Y, Zhang Y, Zhang W, Yuan Y, Bao J, et al. Molecular basis of binding between novel human coronavirus MERSCoV and its receptor CD26. Nature 2013; 500:227-31; PMID:23831647; http://dx.doi.org/10.1038/ nature12328
18. Chen Y, Rajashankar KR, Yang Y, Agnihothram SS, Liu C, Lin YL, Baric RS, Li F. Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. J Virol 2013; 87:10777-83; PMID:23903833; http://dx.doi.org/ 10.1128/JVI.01756-13
19. Wang N, Shi X, Jiang L, Zhang S, Wang D, Tong P, Guo D, Fu L, Cui Y, Liu X, et al. Structure of MERSCoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 2013; 23:986-93; PMID:23835475; http://dx.doi.org/10.1038/ cr.2013.92
20. Zhang N, Jiang S, Du L. Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines 2014; 13:761-74; PMID:24766432; http://dx.doi.org/10.1586/ 14760584.2014.912134
21. Ma C, Li Y, Wang L, Zhao G, Tao X, Tseng CT, Zhou Y, Du L, Jiang S. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine 2014; 32:2100-8; PMID:24560617; http://dx.doi. org/10.1016/j.vaccine.2014.02.004
22. Du L, Kou Z, Ma C, Tao X, Wang L, Zhao G, Chen Y, Yu F, Tseng CT, Zhou Y, et al. A truncated receptorbinding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One 2013; 8:e81587; PMID:24324708; http://dx.doi.org/10.1371/journal. pone.0081587
23. Ma C, Wang L, Tao X, Zhang N, Yang Y, Tseng CT, Li F, Zhou Y, Jiang S, Du L. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments-the importance of immunofocusing in subunit vaccine design. Vaccine 2014; 32:6170-6; PMID:25240756; http:// dx.doi.org/10.1016/j.vaccine.2014.08.086
24. Du L, Zhao G, Kou Z, Ma C, Sun S, Poon VK, Lu L, Wang L, Debnath AK, Zheng BJ, et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 2013; 87:9939-42; PMID:23824801; http://dx.doi.org/10.1128/ JVI.01048-13
25. Mou H, Raj VS, van Kuppeveld FJ, Rottier PJ, Haagmans BL, Bosch BJ. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol 2013; 87:9379-83; PMID:23785207; http://dx.doi.org/ 10.1128/JVI.01277-13
26. Zhang N, Tang J, Lu L, Jiang S, Du L. Receptor-binding domain-based subunit vaccines against MERSCoV. Virus Res 2014; S0168-1702:00473-0; PMID:25445336; http://dx.doi.org/10.1016/j. virusres.2014.11.013
27. Zhang N, Channappanavar R, Ma C, Wang L, Tang J, Garron T, Tao X, Tasneem S, Lu L, Tseng CT, et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol 2015; PMID:25640653; http://dx.doi.org/10.1038/ cmi.2015.03
28. Song F, Fux R, Provacia LB, Volz A, Eickmann M, Becker S, Osterhaus AD, Haagmans BL, Sutter G. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus ankara efficiently induces virus-neutralizing antibodies. J Virol 2013; 87:11950-4; PMID:23986586; http://dx.doi. org/10.1128/JVI.01672-13
29. Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, AlHajri F, Osterhaus AD, Haagmans BL, Gambotto A. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice. Vaccine 2014; 32:5975-82; PMID:25192975; http://dx.doi.org/10.1016/j. vaccine.2014.08.058
30. Almazan F, DeDiego ML, Sola I, Zuniga S, Nieto-Torres JL, Marquez-Jurado S, Andres G, Enjuanes L. Engineering a replication-competent, propagationdefective Middle East respiratory syndrome coronavirus as a vaccine candidate. MBio 2013; 4:e00650-13; PMID:24023385; http://dx.doi.org/10.1128/ mBio.00650-13
31. Coleman CM, Liu YV, Mu H, Taylor JK, Massare M, Flyer DC, Glenn GM, Smith GE, Frieman MB. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 2014; 32:3169-74; PMID:24736006; http://dx.doi. org/10.1016/j.vaccine.2014.04.016
32. Zhang N, Zheng B, Lu L, Zhou Y, Jiang S, Du L. Advancements in the development of subunit influenza vaccines. Microbes Infect 2014; 17:123-34; PMID:25529753; http://dx.doi.org/10.1016/j. micinf.2014.12.006
33. Belshe RB, Frey SE, Graham I, Mulligan MJ, Edupuganti S, Jackson LA, Wald A, Poland G, Jacobson R, Keyserling HL, et al. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis 2011; 203:666-73; PMID:21282194; http://dx.doi.org/ 10.1093/infdis/jiq093
34. Frey SE, Harrison C, Pass RF, Yang E, Boken D, Sekulovich RE, Percell S, Izu AE, Hirabayashi S, Burke RL, et al. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J Infect Dis 1999; 180:1700-3; PMID:10515836; http://dx.doi.org/ 10.1086/315060
35. Du L, Zhao G, Sun S, Zhang X, Zhou X, Guo Y, Li Y, Zhou Y, Jiang S. A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection. PLoS One 2013; 8:e53568; PMID:23320093; http://dx.doi.org/10.1371/journal. pone.0053568
36. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine 2008; 26:3209-22; PMID:18462843; http://dx.doi.org/ 10.1016/j.vaccine.2008.03.093
37. Du L, Zhao G, Yang Y, Qiu H, Wang L, Kou Z, Tao X, Yu H, Sun S, Tseng CT, et al. A conformationdependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol 2014; 88:7045-53; PMID:24719424; http://dx.doi. org/10.1128/JVI.00433-14
38. Zhao G, Du L, Ma C, Li Y, Li L, Poon VK, Wang L, Yu F, Zheng BJ, Jiang S, et al. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virol J 2013; 10:266; PMID:23978242; http://dx.doi. org/10.1186/1743-422X-10-266
39. Du L, Zhao G, Zhang X, Liu Z, Yu H, Zheng BJ, Zhou Y, Jiang S. Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies. Biochem Biophys Res Commun 2010; 397:580-5; PMID:20617558; http://dx.doi.org/10.1016/j. bbrc.2010.05.161
40. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58:621-81; PMID:16968952; http://dx.doi.org/ 10.1124/pr.58.3.10
41. Tao X, Hill TE, Morimoto C, Peters CJ, Ksiazek TG, Tseng CT. Bilateral entry and release of Middle East respiratory syndrome coronavirus induces profound apoptosis of human bronchial epithelial cells. J Virol 2013; 87:9953-8; PMID:23824802; http://dx.doi.org/ 10.1128/JVI.01562-13
42. Du L, Zhao G, Lin Y, Sui H, Chan C, Ma S, He Y, Jiang S, Wu C, Yuen KY, et al. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides longterm protection against SARS-CoV infection. J Immunol 2008; 180:948-56; PMID:18178835; http://dx. doi.org/10.4049/jimmunol.180.2.948
43. Du L, Zhao G, Lin Y, Chan C, He Y, Jiang S, Wu C, Jin DY, Yuen KY, Zhou Y, et al. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARSCoV infection. Vaccine 2008; 26:1644-51; PMID:18289745; http://dx.doi.org/10.1016/j. vaccine.2008.01.025